Form 8-K - Current report:
SEC Accession No. 0001731122-25-000521
Filing Date
2025-04-03
Accepted
2025-04-03 11:00:41
Documents
13
Period of Report
2025-04-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6489_8k.htm   iXBRL 8-K 26642
  Complete submission text file 0001731122-25-000521.txt   202441

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vrpx-20250402.xsd EX-101.SCH 3026
3 XBRL LABEL FILE vrpx-20250402_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE vrpx-20250402_pre.xml EX-101.PRE 22366
15 EXTRACTED XBRL INSTANCE DOCUMENT e6489_8k_htm.xml XML 3806
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 25807981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)